NAPLEX Quiz: Medication Reconciliation

What this quiz covers

This quiz focuses on Medication Reconciliation, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Advise taking levothyroxine at the same time as calcium and iron to improve adherence
2. Recommend separating levothyroxine from calcium, iron, and fiber by at least 4 hours to reduce absorption interactions (correct answer)
3. Discontinue omeprazole because it will cause acute liver injury with levothyroxine
4. Increase levothyroxine to 200 mcg once daily immediately without addressing administration timing

Explanation: This question tests knowledge of drug-supplement interactions affecting thyroid hormone absorption during medication reconciliation. The patient has an elevated TSH of 6.8 mIU/L despite levothyroxine therapy, with multiple concurrent medications and supplements known to impair levothyroxine absorption including calcium, iron, and fiber. Recommending separation of levothyroxine from calcium, iron, and fiber by at least 4 hours (option B) is the best intervention because these agents significantly reduce levothyroxine absorption through chelation and binding in the GI tract, leading to therapeutic failure as evidenced by the elevated TSH. Taking levothyroxine with these supplements (option A) would worsen the interaction and is inappropriate. Discontinuing omeprazole (option C) is unnecessary as PPIs may slightly reduce absorption but don't cause liver injury with levothyroxine. Increasing the dose (option D) without addressing the timing interaction would not solve the underlying absorption problem. When conducting medication reconciliation for thyroid patients, always assess administration timing of levothyroxine relative to calcium, iron, fiber, and other binding agents - proper spacing can often normalize thyroid function without dose adjustments.

Question 2

1. Sertraline 50 mg by mouth daily
2. Ethinyl estradiol/levonorgestrel 1 tablet by mouth daily
3. Trimethoprim-sulfamethoxazole DS 1 tablet by mouth twice daily (correct answer)
4. Acetaminophen 650 mg by mouth every 6 hours as needed

Explanation: This question tests the recognition of contraindications based on documented allergies during medication dispensing and reconciliation. The key patient-specific factor is the patient's anaphylactic allergy to sulfa drugs, making trimethoprim-sulfamethoxazole (TMP-SMX) inappropriate due to the sulfonamide component. Discontinuing TMP-SMX is the best choice to prevent a severe allergic reaction while treating the infection with an alternative. Sertraline, ethinyl estradiol/levonorgestrel, and acetaminophen are not sulfa-related and pose no allergy risk in this context. A transferable clinical pearl is to always verify allergy details and cross-reactivities before dispensing high-risk medications. Best practices for medication reconciliation include updating allergy profiles and consulting prescribers for alternatives when contraindications are identified.

Question 3

1. Lisinopril and losartan (both act on the renin-angiotensin system) used together (correct answer)
2. Hydrochlorothiazide and potassium supplement used together
3. Ibuprofen and hydrochlorothiazide used together
4. Lisinopril and hydrochlorothiazide used together

Explanation: This question tests the identification of therapeutic duplications in antihypertensive therapy during medication reconciliation. The key patient-specific factor is the concurrent use of lisinopril and losartan, both targeting the renin-angiotensin system, which can lead to hyperkalemia as evidenced by the elevated potassium level. Identifying this duplication is the most significant because it directly contributes to the patient's hyperkalemia and potential renal impairment. Hydrochlorothiazide and potassium supplement together may cause hyperkalemia but is less critical than the ACEI-ARB duplication; ibuprofen and hydrochlorothiazide can reduce diuretic efficacy but do not explain the labs; lisinopril and hydrochlorothiazide is an appropriate combination without duplication. A transferable clinical pearl is to screen for duplications in the same pharmacologic class to prevent additive adverse effects. Best practices include cross-referencing medication lists from multiple sources and correlating with lab values during reconciliation.

Question 4

1. Warfarin plus naproxen increasing bleeding risk (correct answer)
2. Metformin plus metoprolol causing severe hypoglycemia due to reduced metformin clearance
3. Warfarin plus glucosamine/chondroitin causing reduced anticoagulation and thrombosis
4. Metoprolol plus naproxen causing life-threatening bradycardia

Explanation: This question evaluates the ability to identify dangerous drug interactions during medication reconciliation in an anticoagulated patient. The patient has a significantly elevated INR of 4.6 (goal 2-3) and is taking warfarin with naproxen, which represents a major drug interaction due to increased bleeding risk through multiple mechanisms. Warfarin plus naproxen (option A) is the most concerning interaction because NSAIDs like naproxen inhibit platelet aggregation, can cause GI ulceration, and may displace warfarin from protein binding sites, all contributing to increased bleeding risk with an already supratherapeutic INR. Metformin plus metoprolol (option B) does not cause hypoglycemia or affect metformin clearance - this is a safe combination. Warfarin plus glucosamine/chondroitin (option C) may potentially increase INR in some patients but would not cause reduced anticoagulation. Metoprolol plus naproxen (option D) does not cause bradycardia through any interaction mechanism. During medication reconciliation for anticoagulated patients, always screen for NSAIDs (prescription and OTC) as they represent one of the most dangerous drug interactions with warfarin, particularly when INR is already elevated.

Question 5

1. Sertraline 50 mg once daily
2. Cetirizine 10 mg once daily
3. Albuterol inhaler as needed
4. Piperacillin/tazobactam 3.375 g intravenously every 6 hours (correct answer)

Explanation: This question tests knowledge of cross-reactivity between beta-lactam antibiotics and appropriate medication reconciliation in patients with severe allergies. The patient has a documented history of anaphylaxis to penicillin (IgE-mediated Type I hypersensitivity with throat swelling and breathing difficulty), and piperacillin/tazobactam contains a penicillin derivative that poses significant cross-reactivity risk. Piperacillin/tazobactam (option D) must be discontinued immediately due to the high risk of anaphylaxis in a patient with documented severe penicillin allergy - the cross-reactivity rate is nearly 100% for penicillin derivatives. Sertraline (option A), cetirizine (option B), and albuterol (option C) have no cross-reactivity with penicillin and are safe to continue. The presence of tazobactam (a beta-lactamase inhibitor) does not eliminate the allergic risk from piperacillin. When performing medication reconciliation, always verify allergies against newly prescribed medications, particularly with beta-lactam antibiotics where cross-reactivity can be life-threatening. Alternative antibiotics without beta-lactam structures (fluoroquinolones, vancomycin, aztreonam) should be considered for patients with true penicillin anaphylaxis.

Question 6

1. Clarify and correct the metoprolol formulation and dosing (succinate once daily vs tartrate twice daily) to prevent excessive beta-blockade (correct answer)
2. Recommend discontinuing atorvastatin 40 mg nightly due to dizziness
3. Increase hydrochlorothiazide from 25 mg once daily to 50 mg once daily for better blood pressure control
4. Add OTC ibuprofen 400 mg every 6 hours as needed for dizziness-related discomfort

Explanation: This question tests the ability to identify and prioritize medication discrepancies during reconciliation that could cause immediate patient harm. The patient presents with symptomatic bradycardia (HR 44 bpm) and near-syncope, with a critical discrepancy between metoprolol formulations - the pharmacy shows extended-release succinate once daily while the cardiologist prescribed immediate-release tartrate twice daily, and the patient is taking two doses daily. Clarifying and correcting the metoprolol formulation and dosing (option A) is the highest priority because the patient may be taking double the intended dose or mixing formulations, leading to excessive beta-blockade and symptomatic bradycardia. Discontinuing atorvastatin (option B) is inappropriate as statins don't cause dizziness and are essential for coronary artery disease management. Increasing hydrochlorothiazide (option C) could worsen orthostatic symptoms and isn't indicated with bradycardia present. Adding ibuprofen (option D) would not address the underlying cause and could interact with aspirin. When conducting medication reconciliation, always prioritize discrepancies that could cause immediate harm, particularly with high-risk medications like beta-blockers where formulation differences significantly impact dosing frequency and clinical effects.

Question 7

1. Recommend avoiding naproxen while on dual antiplatelet therapy due to increased bleeding risk and suggest acetaminophen as an alternative (correct answer)
2. Stop rosuvastatin because it increases bleeding when combined with aspirin
3. Increase naproxen to 440 mg twice daily to reduce inflammation and prevent stroke
4. Discontinue omeprazole because it prevents aspirin absorption and increases clotting

Explanation: This question tests the optimization of post-TIA regimens by addressing NSAID use with antiplatelets during discharge reconciliation. The key patient-specific factor is naproxen's concurrent use with aspirin and clopidogrel, increasing gastrointestinal bleeding risk. Recommending avoidance of naproxen and suggesting acetaminophen is the best choice to minimize bleeding while managing pain. Stopping rosuvastatin is incorrect as it is indicated; increasing naproxen worsens risk; discontinuing omeprazole removes gastroprotection. A transferable clinical pearl is to prefer non-NSAID analgesics in patients on dual antiplatelet therapy. Best practices include reviewing home OTCs against discharge plans and monitoring hemoglobin.

Question 8

1. Tiotropium and umeclidinium (both long-acting muscarinic antagonists) (correct answer)
2. Tiotropium and albuterol (both bronchodilators)
3. Albuterol and umeclidinium (both short-acting beta agonists)
4. No duplication; all agents are required after a COPD exacerbation

Explanation: This question tests the identification of therapeutic duplications in inhaled COPD therapies during post-discharge reconciliation. The key patient-specific factor is the concurrent tiotropium and umeclidinium, both LAMAs, risking anticholinergic side effects without added benefit. This duplication is most significant because it represents redundant therapy post-exacerbation. Tiotropium and albuterol are complementary; albuterol and umeclidinium are not both short-acting; no duplication does not apply as LAMAs overlap. A transferable clinical pearl is to avoid dual LAMA therapy; choose one based on device preference. Best practices include comparing discharge and home inhalers for class overlaps.

Question 9

1. Instruct the patient to take apixaban and warfarin together long-term for stronger anticoagulation
2. Clarify and prevent unintended concurrent warfarin and apixaban use; contact prescriber to confirm transition plan (correct answer)
3. Reduce apixaban to 2.5 mg twice daily because INR is therapeutic
4. Stop apixaban and continue warfarin because INR is already in range

Explanation: This question tests the prevention of anticoagulant overlaps during post-DVT discharge counseling and reconciliation. The key patient-specific factor is the patient's plan for concurrent warfarin and apixaban, risking supratherapeutic anticoagulation and bleeding. Clarifying and preventing this is the best choice to ensure safe transition per guidelines. Instructing long-term combination is dangerous; reducing apixaban ignores the overlap; stopping apixaban abruptly risks thrombosis. A transferable clinical pearl is to overlap warfarin with DOACs only until INR is therapeutic during switches. Best practices include patient education on transitions and confirming understanding.

Question 10

1. Continue lisinopril 20 mg daily with sacubitril/valsartan to improve heart failure outcomes
2. Hold carvedilol until symptoms improve, then restart in 2 weeks
3. Instruct the patient to stop lisinopril and contact the prescriber due to risk with sacubitril/valsartan and hyperkalemia (correct answer)
4. Increase potassium chloride to 40 mEq daily because loop diuretics lower potassium

Explanation: This question tests the optimization of heart failure regimens by identifying contraindications and lab abnormalities during post-discharge reconciliation. The key patient-specific factor is the concurrent use of lisinopril and sacubitril/valsartan, which can cause severe hyperkalemia and angioedema, compounded by elevated potassium and SCr. Instructing the patient to stop lisinopril and contact the prescriber is the best choice to mitigate risks of hyperkalemia and dual renin-angiotensin inhibition. Continuing both is contraindicated and worsens hyperkalemia; holding carvedilol is suboptimal as it is essential for HFrEF; increasing potassium exacerbates hyperkalemia. A transferable clinical pearl is to avoid combining ACE inhibitors with ARNI therapy, with a mandatory 36-hour washout period. Best practices include reviewing discharge summaries against home meds and monitoring electrolytes in heart failure patients.

Question 11

1. Advise separating levothyroxine from calcium and iron by at least 4 hours to improve absorption (correct answer)
2. Stop levothyroxine and continue calcium and iron because TSH is high
3. Take levothyroxine with calcium to protect the stomach and improve tolerability
4. Increase calcium carbonate to 2000 mg daily to normalize TSH

Explanation: This question tests the identification of administration-related interactions affecting drug absorption during reconciliation. The key patient-specific factor is the concurrent timing of levothyroxine with calcium and iron, reducing its absorption and leading to elevated TSH. Advising separation by at least 4 hours is the best choice to optimize thyroid control. Stopping levothyroxine is incorrect; taking with calcium does not improve tolerability; increasing calcium does not address TSH. A transferable clinical pearl is to take levothyroxine on an empty stomach, separated from interacting supplements. Best practices include counseling on timing and correlating with thyroid labs.

Question 12

1. Excess sympathomimetic use (albuterol plus OTC ephedrine) may worsen tachycardia and hypokalemia (correct answer)
2. Fluticasone/salmeterol will inactivate albuterol; stop fluticasone/salmeterol
3. Guaifenesin will cause severe bronchospasm when combined with albuterol
4. Ephedrine will prevent steroid absorption and cause adrenal crisis

Explanation: This question tests the identification of OTC sympathomimetic overuse contributing to asthma exacerbations and electrolyte imbalances. The key patient-specific factor is the excess use of albuterol and ephedrine, both beta-agonists, worsening tachycardia and hypokalemia. This interaction is most concerning because it can precipitate arrhythmias and exacerbate asthma symptoms. Fluticasone/salmeterol does not inactivate albuterol; guaifenesin does not cause bronchospasm; ephedrine does not cause adrenal crisis. A transferable clinical pearl is to limit sympathomimetic overuse in asthma to prevent tachyphylaxis and hypokalemia. Best practices include educating on OTC risks and ensuring adherence to controller therapies during reconciliation.

Question 13

1. Recommend stopping OTC potassium and avoiding salt substitutes; notify prescriber due to hyperkalemia risk with lisinopril and reduced kidney function (correct answer)
2. Increase potassium supplement to three times daily to prevent cramps
3. Stop lisinopril immediately and start hydrochlorothiazide 50 mg daily without prescriber input
4. Continue all products and recheck potassium in 6 months

Explanation: This question tests the management of hyperkalemia risks from OTC supplements in renally impaired patients during refill reconciliation. The key patient-specific factor is the OTC potassium and salt substitutes with lisinopril, contributing to hyperkalemia and elevated SCr. Recommending discontinuation and notifying the prescriber is the best choice to prevent cardiac complications. Increasing potassium worsens hyperkalemia; stopping lisinopril without input is inappropriate; continuing all delays intervention. A transferable clinical pearl is to advise against potassium supplements in ACEI users without monitoring. Best practices include inquiring about OTCs and correlating with electrolyte labs.

Question 14

1. Confirm indication for aspirin and recommend discontinuation unless a clear secondary prevention indication exists due to bleeding risk with rivaroxaban (correct answer)
2. Stop pantoprazole because it can reduce iron absorption
3. Increase rivaroxaban to 30 mg daily to prevent stroke after a bleed
4. Add ibuprofen 400 mg as needed for pain to avoid opioid use

Explanation: This question tests the evaluation of unnecessary antiplatelet use in anticoagulated patients post-GI bleed during reconciliation. The key patient-specific factor is the self-initiated aspirin with rivaroxaban, increasing bleeding risk without a clear indication, as evidenced by low hemoglobin. Confirming the indication and recommending discontinuation is the best choice unless secondary prevention is warranted. Stopping pantoprazole is suboptimal as it aids healing; increasing rivaroxaban is dangerous; adding ibuprofen worsens bleeding. A transferable clinical pearl is to avoid aspirin in AFib patients on DOACs without CAD indications. Best practices include clarifying self-medication and monitoring for bleeding signs.

Question 15

1. Combined serotonergic agents (sertraline plus tramadol and cyclobenzaprine) increasing risk of serotonin syndrome and CNS depression (correct answer)
2. Diphenhydramine will reduce sertraline absorption and cause treatment failure
3. Cyclobenzaprine will increase kidney clearance of tramadol leading to withdrawal
4. Tramadol will prevent diphenhydramine from causing sedation

Explanation: This question tests the recognition of additive serotonergic and CNS depressant effects in pain and psychiatric regimens during reconciliation. The key patient-specific factor is the combination of sertraline, tramadol, and cyclobenzaprine, heightening serotonin syndrome and sedation risks. This interaction is most concerning due to potential for life-threatening symptoms. Diphenhydramine does not reduce sertraline absorption; cyclobenzaprine does not increase tramadol clearance; tramadol does not prevent diphenhydramine sedation. A transferable clinical pearl is to monitor for serotonin syndrome signs with multiple serotonergic agents. Best practices include assessing additive effects in polypharmacy for pain and mood.

Question 16

1. Trimethoprim/sulfamethoxazole 160/800 mg twice daily (correct answer)
2. Lamotrigine 200 mg once daily
3. Ethinyl estradiol/levonorgestrel 1 tablet once daily
4. Dandelion extract supplement once daily

Explanation: This question evaluates recognition of severe drug allergies and appropriate medication reconciliation to prevent life-threatening reactions. The patient has a documented history of Stevens-Johnson syndrome (SJS) from sulfonamide antibiotics 5 years ago, and has been prescribed trimethoprim/sulfamethoxazole which contains sulfamethoxazole, a sulfonamide antibiotic. Trimethoprim/sulfamethoxazole (option A) must be discontinued immediately because SJS is a severe, life-threatening drug reaction with high risk of recurrence upon re-exposure to the causative drug class - sulfonamide antibiotics are absolutely contraindicated in patients with prior SJS from sulfonamides. Lamotrigine (option B), while capable of causing SJS independently, is not contraindicated based on sulfonamide allergy. Ethinyl estradiol/levonorgestrel (option C) has no relation to sulfonamide allergy. Dandelion extract (option D) is not a sulfonamide despite being called a "water pill." During medication reconciliation, severe drug reactions like SJS, TEN, anaphylaxis, or DRESS syndrome represent absolute contraindications to rechallenge with the causative drug class - alternative antibiotics like nitrofurantoin, fosfomycin, or fluoroquinolones should be used for UTI treatment in this patient.

Question 17

1. Sitagliptin and semaglutide (incretin-based therapies) used together without added benefit (correct answer)
2. Metformin and semaglutide used together
3. Atorvastatin and semaglutide used together
4. Metformin and sitagliptin used together

Explanation: This question evaluates the identification of therapeutic duplication in diabetes management during medication reconciliation, focusing on incretin-based therapies. The key patient-specific factor is the concurrent use of sitagliptin and semaglutide, despite the endocrinologist's instruction to discontinue sitagliptin, leading to overlapping mechanisms without additional glycemic benefit. Identifying sitagliptin and semaglutide as the most significant duplication is the best choice because both target the incretin pathway—sitagliptin inhibits DPP-4 to increase endogenous GLP-1, while semaglutide directly agonizes GLP-1 receptors—potentially increasing side effects like gastrointestinal upset without improved efficacy. Metformin and semaglutide together is not a duplication, as they have complementary mechanisms and are commonly combined for better A1c control; atorvastatin and semaglutide have no overlapping therapeutic effects, with atorvastatin addressing dyslipidemia. Metformin and sitagliptin together is a standard combination without duplication issues, unlike the incretin overlap. A transferable clinical pearl is to review specialist notes during reconciliation to ensure alignment with the full medication list. Decision frameworks should prioritize de-prescribing redundant therapies to minimize adverse effects and optimize patient adherence.

Question 18

1. Clarify whether clopidogrel should be continued or stopped to avoid unintended dual antiplatelet therapy or premature discontinuation (correct answer)
2. Stop atorvastatin because high-intensity statins increase stroke risk
3. Increase aspirin to 325 mg daily because clopidogrel is missing
4. Add vitamin E 400 units daily for secondary stroke prevention

Explanation: This question tests the clarification of antithrombotic continuity post-stroke during discharge reconciliation. The key patient-specific factor is the omission of clopidogrel from the discharge list, risking either premature discontinuation or unintended dual therapy. Clarifying continuation is the best choice to align with CAD history and prevent thrombotic events. Stopping atorvastatin is incorrect as it is beneficial; increasing aspirin is unnecessary; adding vitamin E lacks evidence. A transferable clinical pearl is to evaluate DAPT duration based on stent type and timing. Best practices include reviewing prior therapies against discharge plans for omissions.

Question 19

1. Verify the intended lamotrigine dose with the prescriber and update the medication list to prevent subtherapeutic dosing and seizures (correct answer)
2. Recommend stopping folic acid because it reduces antiepileptic efficacy
3. Advise doubling the caffeine supplement to improve alertness and adherence
4. Remove lamotrigine from the profile because dose changes are not handled by pharmacies

Explanation: This question tests the resolution of dosing discrepancies in antiepileptic therapy during refill reconciliation. The key patient-specific factor is the unreconciled lamotrigine dose increase, leading to alternating and potential subtherapeutic levels. Verifying and updating the dose is the best choice to prevent seizures and ensure adherence. Stopping folic acid is unnecessary as it is beneficial; doubling caffeine is inappropriate; removing from profile ignores the issue. A transferable clinical pearl is to titrate lamotrigine slowly to minimize rash risk. Best practices include prescriber verification for dose changes and synchronizing refills.

Question 20

1. Pseudoephedrine may increase blood pressure and counteract antihypertensive control (correct answer)
2. Dextromethorphan will cause severe hypoglycemia with insulin glargine
3. Pseudoephedrine will reduce metformin absorption and cause lactic acidosis
4. Dextromethorphan will inactivate glipizide and cause hyperkalemia

Explanation: This question tests the identification of significant drug interactions in patients with comorbidities during comprehensive medication reviews. The key patient-specific factor is the patient's hypertension and elevated blood pressure, exacerbated by pseudoephedrine's sympathomimetic effects. Pseudoephedrine increasing blood pressure is the most concerning because it directly counteracts antihypertensive control in this diabetic patient. Dextromethorphan does not cause hypoglycemia with insulin; pseudoephedrine does not reduce metformin absorption; dextromethorphan does not inactivate glipizide or cause hyperkalemia. A transferable clinical pearl is to caution patients with hypertension against OTC sympathomimetics like pseudoephedrine. Best practices for reconciliation include assessing OTC use and correlating with vital signs and labs.